A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer

NCT02141295 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

197

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: 5-FU
DRUG: Bevacizumab
DRUG: Folinic acid
DRUG: Oxaliplatin
DRUG: Vanucizumab

Sponsor

Hoffmann-La Roche